Who signed AEON Biopharma’s 8-K related to the Corporate Presentation?

The 8-K was signed on behalf of AEON Biopharma, Inc. by Robert Bancroft, the company’s Chief Executive Officer.

AEON Biopharma (AEON) shares updated Corporate Presentation for investors

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)

Form Type

8-K

Rhea-AI Filing Summary

AEON Biopharma, Inc. furnished an investor presentation as part of a corporate update. On September 8, 2025, the company made a “Corporate Presentation” available in the investor relations section of its website and attached it as Exhibit 99.1. Management may use this presentation in future meetings to discuss the company. The materials include a slide on forward-looking statements that outlines important cautionary information. The presentation and related information are furnished, not filed, so they are not automatically subject to certain Exchange Act liabilities or incorporated into other securities law filings unless specifically referenced.

8-K Event Classification

2 items: 7.01, 9.01

2 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Understanding 8-K Material Events →

Accepted by SEC EDGAR 09/08/2025 - 05:00 PM

FAQ

What did AEON (AEON) disclose in this 8-K filing?

AEON Biopharma, Inc. disclosed that it made an investor “Corporate Presentation” available on its website and furnished it as Exhibit 99.1. The presentation may be used by management in future meetings to discuss the company.

Where can investors find AEON Biopharma’s new Corporate Presentation?

The Corporate Presentation is available in the investor relations section of AEON Biopharma’s website and is also attached to the 8-K as Exhibit 99.1, dated September 2025.

Is AEON Biopharma’s Corporate Presentation considered filed with the SEC?

No. The information in Item 7.01, including Exhibit 99.1, is furnished, not filed, and is not subject to Section 18 liability or incorporated into other securities law filings unless expressly referenced.

What cautionary information does AEON include with the Corporate Presentation?

AEON Biopharma refers investors to the “Forward-Looking Statements” slide in the Corporate Presentation, which contains important information about forward-looking statements.

What exhibits are attached to AEON Biopharma’s 8-K?

The 8-K includes Exhibit 99.1, the Corporate Presentation dated September 2025, and Exhibit 104, the Cover Page Interactive Data File embedded within the Inline XBRL document.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 8, 2025

AEON Biopharma, Inc.

(Exact name of registrant as specified in its charter)

Delaware

001-40021

85-3940478

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification Number)

5 Park Plaza

Suite 1750

Irvine, CA 92614

(Address of principal executive offices, including Zip Code)

Registrant’s telephone number, including area code: (949) 354-6499

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol	Name of each exchange on which registered
Class A Common Stock, $0.0001 par value per share	AEON	NYSE American

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01. Regulation FD Disclosure.

On September 8, 2025, AEON Biopharma, Inc. (the “Company” or “AEON”) made available in the investor relations section of its website a presentation (the “Corporate Presentation”), a copy of which is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.

The information from the Corporate Presentation may also be used by the management of the Company in future meetings regarding the Company. For important information about forward-looking statements in the Corporate Presentation, see the slide titled “Forward-Looking Statements” in Exhibit 99.1 attached hereto.

The information furnished in this Item 7.01 of this Current Report (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing, unless expressly incorporated by specific reference in such a filing.

Item 9.01. Financial Statement and Exhibits.

(d) Exhibits.



Exhibit No.							Description

99.1							Corporate Presentation, dated September 2025.
104							Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


	AEON Biopharma, Inc.
Date: September 8, 2025	By:	/s/ Robert Bancroft
		Robert Bancroft
		Chief Executive Officer

Source: View Original Filing on SEC EDGAR